Table 3.

Promoters and reasons of switch to rivastigmine patches

	Evaluable patients (n = 1022)
Promoter of switch, n (%)
Physician	842 (82.39)
Patient	106 (10.37)
Caregiver	217 (21.23)
Reason for switch, n (%)
Improving the ease of administration	579 (56.65)
Lack of efficacy/improving efficacy	323 (31.60)
Intolerability/improving tolerability	376 (36.79)
Poor adherence to treatment (not due to intolerability)	190 (18.59)
Physical diseases impairing administration	19 (1.86)
Rejection by the patient	79 (7.73)
Difficulty of medication management	70 (6.85)
Excessive caregiver burden	58 (5.67)

Note: Subjects were allowed to indicate several promoters and reasons.